XML 71 R56.htm IDEA: XBRL DOCUMENT
v3.24.3

License Agreements - MacroGenics (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 84 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Mar. 31, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Jul. 24, 2024 | Dec. 31, 2023
License Agreements |  |  |  |  |  |  |  |
Research and development |  | $ 573,174 | $ 375,709 | $ 2,140,814 | $ 1,183,100 |  |  |
MacroGenics |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Milestone payment made under license agreement |  | 100,000 |  | 100,000 |  |  |  |
License agreement, amount payable for waiver of certain future milestones payment |  |  |  |  |  |  | $ 100,000 |
Research and development |  | 15,500 | $ 12,900 | 40,800 | $ 42,800 |  |  |
Accrued and other liabilities |  | 900 |  | $ 900 |  | $ 900 |  | $ 300
MacroGenics | Minimum |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 15.00% |  |  |  |
MacroGenics | Maximum |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  |  | 24.00% |  |  |  |
Regulatory Milestone | MacroGenics |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Milestone payment made under license agreement | $ 15,000 |  |  |  |  |  |  |
Milestone payment, estimated useful life (in years) |  |  |  | 13 years 6 months |  |  |  |
Developmental and Regulatory Milestones | MacroGenics |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Milestone payment made under license agreement |  |  |  |  |  | 215,000 |  |
Development and Regulatory Milestones | MacroGenics | Maximum |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  | 210,000 |  | $ 210,000 |  | 210,000 |  |
Commercialization Milestones | MacroGenics | Maximum |  |  |  |  |  |  |  |
License Agreements |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  | $ 330,000 |  | $ 330,000 |  | $ 330,000 |  |

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Agreement, Amount Payable For Waiver Of Certain Future Milestones + References No definition available. + Details
Name: | incy_LicenseAgreementAmountPayableForWaiverOfCertainFutureMilestones
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of the milestone payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement Milestone Payment, Useful Life + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentUsefulLife
Namespace Prefix: | incy_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MacroGenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |